Lutikizumab (ABT-981) is an investigational monoclonal antibody targeting IL-1α and IL-1β [6
], designed using proprietary technology to create dual variable domain antibodies ('DVD-IgTM
]. DVD-Igs are single pharmaceutical agents capable of simultaneously targeting two mediators of disease. The unique feature of DVD-Igs is that each arm of the antibody contains two tandem variable domains, each capable of binding a different antigen (see Figure 2 in [6
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.